This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
CytomX Therapeutics (CTMX) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
CytomX Therapeutics (CTMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for CytomX Therapeutics (CTMX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 89.47% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 40.91% and 4.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Add ImmunoGen (IMGN) to Your Portfolio Now
by Zacks Equity Research
ImmunoGen's (IMGN) recently launched drug, Elahere, is expected to generate incremental revenues for the company and boost its top-line growth in the next few years.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 68.75% and 5.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Codexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Codexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Certara, Inc. (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -100% and 94.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 14.29% and 4.96%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 60% and 6.73%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of -2.38% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX (CTMX) Up 55% on Strategic Partnership With Moderna
by Zacks Equity Research
CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023.
Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update
by Zacks Equity Research
Updates from CTMX and APLS are the key highlights from the biotech sector during the past week.
CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron
by Zacks Equity Research
CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.
CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -9.38% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Travere (TVTX) delivered earnings and revenue surprises of -12.37% and 4.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.78% and 1.42%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CytomX Therapeutics (CTMX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -5.71% and 21.42%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 16.95% and 55.09%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?